Aberrant microRNA (miRNA) expression is a defining feature of human malignancy. Specific miRNAs have been identified as promoters or suppressors of metastatic progression. miRNAs control metastasis through divergent or convergent regulation of metastatic gene pathways. Some miRNA regulatory networks govern cell-autonomous cancer phenotypes, whereas others modulate the cell-extrinsic composition of the metastatic microenvironment. The use of small RNAs as probes into the molecular and cellular underpinnings of metastasis holds promise for the identification of candidate genes for potential therapeutic intervention.
Epithelial carcinomas are the predominant cancer types that kill humans by metastasizing from their tissues of origin to distal organs. Nevertheless, the cell-biological pathways regulating the multi-step metastatic cascade had not been adequately characterized until recently [1] [2] [3] . Several technological advances during the past decade have greatly increased our molecular and conceptual understanding of this process. The development of whole-genome profiling approaches has permitted global analysis of the cancer transcriptome, whereas RNA-interference tools and human cancer xenograft models have facilitated functional testing of specific genes in metastasis. A key concept that emerged from early mouse studies was that metastatic colonization requires the actions of many gene products [4] [5] [6] . These functional findings were corroborated by transcriptomic studies of human breast cancers, which revealed large sets of genes to be recurrently overexpressed in primary tumours that metastasize 7 . An outstanding question in the field at that time was how such concerted pro-metastatic gene expression states were attained. In recent years, small non-coding RNAs, or miRNAs, have emerged as a class of post-transcriptional regulators that displays a pervasive role in this type of coordinated gene expression control [8] [9] [10] [11] [12] [13] . In this review, we provide a conceptual overview of the molecular and cellular processes governed by endogenous miRNAs during metastatic progression.
Basics of miRNA biogenesis and action
Although the majority of human miRNAs reside in intergenic regions or within the introns of genes, exonic miRNAs have also been described 14 . Transcription of a single or multiple concatenated miRNAcoding sequences is mediated by RNA polymerase II, and less frequently by RNA polymerase III, yielding a primary miRNA transcript (pri-miRNA) 15, 16 . Mammalian pri-miRNAs are processed through a series of cleavage steps [15] [16] [17] [18] . Initially, the RNA-binding protein DGCR8 recognizes and binds to double-stranded hairpin structures embedded in the pri-miRNA. This interaction allows the ribonuclease Drosha, which forms a complex with DGCR8, to cleave the pri-miRNA at the hairpin junction site, releasing a roughly 70-nucleotide-long stem-loop product known as the pre-miRNA [15] [16] [17] . Association of the pre-miRNA with Exportin-5 and its cofactor Ran-GTP facilitates its nuclear export 15, 16 . Once in the cytoplasm, the ribonuclease Dicer bound to its cofactor, the RNA-binding protein TARBP2, cleaves the pre-miRNA to yield a 21-26-nucleotide-long miRNA-miRNA* duplex structure 15, 16, 18 . This miRNA duplex is loaded onto the RNA-induced silencing complex (RISC), where the guide miRNA strand is preferentially incorporated into the complex. The complementary passenger miRNA* strand is typically released and degraded, except in cases where the miRNA* strand also mediates silencing [14] [15] [16] 19 . The key effector at the core of RISC is a member of the Argonaut (Ago) family of proteins, which directly interacts with single-stranded mature miRNAs and uses them as guides to recognize mRNAs bearing sequences complementary to the bound miRNA [20] [21] [22] . Ago binding to target mRNAs results in the recruitment of silencing effector proteins such as GW182 (ref. 23) , ultimately leading to mRNA deadenylation and decay and/or translational repression 13, 14 . Although the majority of miRNA regulatory sequences reside in the 3'-untranslated regions of transcripts, interactions of miRNAs with coding sequences have also been mapped [24] [25] [26] . Computational analyses, gene expression profiling, heterologous reporter assays and biochemically coupled transcriptomic deep-sequencing approaches 27, 28 have provided a toolbox for systematic discovery of miRNA target genes.
Deregulated miRNA expression in human cancer
The link between deregulated miRNA expression and cancer had been well established 29, 30 before the identification of these small RNAs as regulators of metastasis. Deregulated miRNA expression in cancer was reported in a study showing that two clustered miRNAs, miR-15a and miR-16, were deleted or downregulated in the majority (>60%) of B-cell chronic lymphocytic leukaemias 31 . Subsequent work demonstrated deregulated 32 and breast 33 carcinomas; let-7 was found to be silenced in lung cancer 34, 35 ; and miR-155, miR-21 and the miR-17-92 cluster were upregulated in breast and lung cancers 33, [35] [36] [37] [38] . Interestingly, miR-21, miR-155 and miR-17-92 were also found to be overexpressed in B-cell and Hodgkin's lymphomas [39] [40] [41] [42] [43] , establishing them as potential oncogenic miRNAs across diverse cancer types. Subsequent miRNA profiling studies revealed distinct expression profiles in various solid and liquid cancers that could inform the diagnosis of these malignancies 29, [44] [45] [46] [47] [48] [49] . Although a small subset of specific oncogenic miRNAs have been found to be upregulated in cancer, global downregulation of expression and processing has emerged as a feature of these regulators during tumorigenesis [50] [51] [52] [53] [54] . Consistent with this, an miRNA family (miR-34a-c) was found to be transcriptionally induced by the key tumour suppressor p53, which is frequently mutated and inactivated in several types of cancer [55] [56] [57] [58] .
Metastasis-suppressive miRNA networks
This early work raised the question of whether silencing of specific miRNAs could modulate metastasis by driving pro-metastatic gene expression programs. The search for miRNAs that repress the expression of pro-metastatic genes and consequently suppress metastasis originally focused on breast cancer 6 . Small RNA profiling of highly metastatic sublines derived from the in vivo selection of a human breast cancer population revealed a subset of miRNAs that were silenced in cells with high metastatic capacity. Functional testing demonstrated that overexpression of miR-335, miR-206 or miR-126 robustly suppressed metastatic colonization by human breast cancer lines. Conversely, antagomir-mediated inhibition of miR-335 enhanced metastasis, providing crucial loss-offunction in vivo evidence for endogenous miRNA activity in the regulation of metastasis. Importantly, the expression levels of these miRNAs in a collection of female breast cancers correlated with these patients' likelihood of metastatic relapse 6 . Several studies have since validated the silenced expression and prognostic capacity of these miRNAs in independent and larger clinical cohorts for diverse cancer types [59] [60] [61] [62] [63] [64] [65] [66] [67] , as well as their tumour-suppressive and/or metastasis-suppressive functions in other breast cancer models 59, 68 and cancer types 67, [69] [70] [71] [72] .
These miRNAs were shown to inhibit metastasis through several mechanisms. Whereas miR-335 and miR-206 suppressed cell invasion 6 , endogenous miR-126 inhibited tumour growth, endothelial recruitment and metastatic initiation by breast cancer cells 73 . Consistent with a role for miRNAs in establishing a metastatic gene expression program, miR-335 silenced a set of pro-metastatic genes, the expression of which was found to correlate with metastatic outcomes in breast cancer patients. Two of these genes, SOX4 and Tenascin-C, were found to drive the miR-335-suppressed phenotypes -cell invasion, migration and metastasis 6 ( Fig. 1a) . SOX4 and Tenascin-C have been subsequently validated as promoters of cancer progression in other models [74] [75] [76] . Another well-characterized example of a metastasis-suppressive miRNA network is that of miR-31 (refs 77-79) (Fig. 1b) . Overexpression of miR-31 in human cancer cells strongly suppressed metastasis, whereas stable miRNA inhibition in otherwise non-metastatic cells led to a robust 10-fold increase in metastatic capacity, consistent with metastasis suppression by endogenous miR-31. Importantly, the expression of miR-31 in primary breast tumours was prognostic of metastatic relapse 77 .
Silencing of miR-31 has also been observed in other cancer types [80] [81] [82] [83] . Mechanistically, miR-31 was found to inhibit metastatic progression through coordinated regulation of three genes -integrin α 5 (ITGA5), radixin (RDX) and RhoA, each of which was shown to promote anoikis resistance and cell invasion [77] [78] [79] (Fig. 1b) . Collectively, these findings illustrate that silencing of robust metastasis-suppressor miRNAs (Table 1) in highly metastatic cells results in the lifting of key post-transcriptional regulatory barriers imposed on pro-invasive genes.
Metastasis-promoting miRNA networks
Could an miRNA conversely promote metastasis by targeting a metastasis-suppressive gene? In a bold series of experiments, miR-10b was identified as a driver of metastasis 84 . Overexpression studies in human breast cancer cells demonstrated sufficiency of miR-10b in promoting metastasis. This miRNA was found to enhance cell migration and invasion through targeting of homeobox D10 (HOXD10), which in turn inhibited the metastasis-promoting gene RhoC (refs 84,85) (Fig. 2a) . Subsequent studies revealed a role for endogenous miR-10b in metastasis as well 86 . miR-373 and miR-520c, which belong to the same miRNA family, were also identified as metastasis-promoting miRNAs 87 . In an innovative forward genetic screen using human breast cancer cells transduced with a miRNA-expression library and assessed for their migration ability, miR-373 and miR-520c were found to be enriched in cells with enhanced migratory capacity. These miRNAs were shown to promote cell migration and invasion by targeting CD44 (Fig. 2b) . Importantly, introduction of miR-373 or miR-520c was sufficient to confer metastatic capacity to otherwise non-metastatic human breast cancer cells 87 . The miR-200 family, which includes miR-200a, miR-200b, miR-200c, miR-141 and miR-429, is another prominent example of a metastasisregulatory network driven by miRNAs. Early work by several independent groups demonstrated that this miRNA family is important in maintaining the tumour epithelial phenotype and inhibiting the epithelial-to-mesenchymal transition (EMT) [88] [89] [90] [91] . This was supported by the strong correlation observed between the levels of miR-200s and the epithelial marker E-cadherin in a collection of cancer lines as well as in clinical samples 88, 90 . Mechanistically, miR-200s were found to inhibit cell migration by directly targeting the transcription factors ZEB1 and ZEB2, which suppress E-cadherin (Fig. 2c) . Overexpression of miR-200s was shown to decrease metastatic dissemination from primary tumours in a syngenic breast cancer mouse model 92 . In addition to the reports indicating a metastasis-suppressive role for the miR-200 family, recent findings have also demonstrated a role for these miRNAs in promoting metastasis 93 . High levels of miR-200s correlated with shorter metastasisfree survival times in breast cancer patients, whereas overexpression of miR-200s enhanced lung colonization by murine breast cancer cells. Interestingly, the metastasis-promoting effects of miR-200s were mediated through downstream targets distinct from the ones implicated in EMT. Targeting of Sec23a, a COPII vesicle component, resulted in decreased secretion of TINAGL1 and IGFBP4 -factors shown to suppress metastasis by mouse breast cancer cells (Fig. 2c) 
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. These findings implicate miR-200s as potential pleiotropic regulators of metastatic progression. Whereas silencing of miR-200s may be beneficial at the early steps of metastasis by triggering EMT through ZEB1/2-dependent repression of E-cadherin, upregulation of miR-200s at distal metastatic sites may actually promote metastatic colonization through Sec23 targeting. These seemingly opposing roles of miR-200s in metastasis could be reconciled by considering the multi-faceted nature of metastasis. It is conceivable that context-dependent miRNA modulation at different steps of the metastatic cascade may drive both promoting and suppressive roles in cancer progression through divergent miRNA targeting of distinct molecular and cellular pathways. Loss-of-function experiments on miR-200s should provide important insights into their complex roles during metastatic progression.
Whereas miR-200s indirectly promote E-cadherin expression to maintain an epithelial phenotype, miR-9 was found to directly target E-cadherin to drive cancer cell motility, invasion and metastasis 94 ( Fig. 2d) . Overexpression of miR-9 enhanced micrometastasis formation by human breast cancer cells, whereas its stable silencing inhibited murine breast cancer metastasis. Subsequent work demonstrated that overexpression of miR-9 in E-cadherin-negative human breast cancer cells enhanced metastasis, suggesting that miR-9 represses further metastasis-suppressive target genes 95 . This study identified leukaemia inhibitory factor receptor (LIFR) as a direct target of miR-9 that mediates its pro-metastatic effects in the absence of E-cadherin. Depletion of LIFR in non-metastatic cells was shown to increase invasion and migration, whereas its overexpression abrogated the metastatic capacity conferred by miR-9. The metastasis-suppressive role of LIFR was found to be mediated through inactivation of YAP, a previously known oncoprotein whose activity is regulated by the Hippo pathway 95 ( Fig. 2d) . In addition to breast cancer, metastasis-regulatory miRNAs have also been identified in multiple other cancer types (Table 1) . At roughly the same time as several reports demonstrating pro-tumorigenic and pro-metastatic roles for miR-21 in breast cancer [96] [97] , another group showed that miR-21 drives colorectal cancer invasion and metastasis by targeting PDCD4 (ref. 98) (Fig. 2e) . TPM1 and Maspin were two other miR-21 targets uncovered in breast cancer 97 . Recently, miR-21 was also shown to drive metastasis of squamous cell carcinoma tumours deficient for p53 (ref. 99 ). Metastasis-regulatory miRNAs have also been described in melanoma, a highly intractable malignancy. Overexpression of miR-182 was initially shown to increase metastasis by mouse melanoma cells 100 . Subsequently, miR-30b/30d were found to correlate with human melanoma progression outcomes and their overexpression in human melanoma cells enhanced micrometastasis formation by targeting the GALNT1 and GALNT7 suppressors of cell invasion 101 (Fig. 2f) . Finally, miR-199a-3p, miR-199a-5p and miR-1908 were recently discovered as endogenous miRNA drivers of human melanoma metastasis. Inhibition of these clinico-pathologically correlated miRNAs in a series of human melanoma lines robustly suppressed metastasis 102 . [88] [89] [90] [91] [92] (red blocking arrow), whereas miR-200-mediated silencing of Sec23a promotes metastatic colonization by inhibiting secretion of TINAGL1 and IGFBP4 (ref. 93) (green blocking arrow). (d) miR-9 enhances breast cancer metastasis by two independent pathways. Direct repression of E-cadherin by miR-9 leads to enhanced cell invasion and migration 94 (red blocking arrow), whereas miR-9 targeting of LIFR results in activation of the Hippo signalling component YAP (ref. 95) (green blocking arrow). MYC/MYCN drives transcription of miR-9 in breast cancer cells 94 . (e) miR-21 promotes cancer cell invasion and metastasis through coordinate suppression of TPM1, PDCD4 and Maspin [96] [97] [98] . The miR-21 target genes have also been shown to suppress cancer cell growth and survival 96, [134] [135] [136] . Active mTOR and STAT3 signalling has been shown to correlate with miR-21 upregulation in cancer cells 99 . (f) miR-30b/30d increases melanoma invasion and metastasis by targeting GALNT1 and GALNT7. GALNT7 reduces the levels of IL-10, a putative immunosuppressive factor 101 .
Cell-intrinsic versus cell-extrinsic effects of metastasisregulatory miRNAs
Early studies ascribed cell-autonomous phenotypes to miRNAs implicated in metastasis. For example, miR-335 (ref. 6 ) and miR-31 (ref. 77) were identified as suppressors of cell migration and invasion ( Fig. 1 [96] [97] [98] were shown to promote these phenotypes (Fig. 2) . Another prominent example of an miRNA regulatory network controlling a cell-intrinsic phenotype is that of the let-7 family [103] [104] [105] ( Fig. 3a) . Let-7 overexpression in human breast cancer cells was initially shown to decrease the incidence of metastatic events to the liver and lung 103 . Subsequent work revealed that let-7-mediated repression of the chromatin-remodelling protein HMGA2 and the transcription factor BACH1, both of which promote the transcription of pro-invasive genes, suppressed cell invasion and metastasis to the bone [104] [105] . Thus, let-7 halts the cell-intrinsic phenotype of cell invasion, which is required for efficient metastasis, by coordinately targeting factors that regulate pro-invasive gene expression programs (Fig. 3a) .
Recently, miRNAs were shown to also have the ability to regulate metastasis through cell-extrinsic modulation of the metastatic microenvironment. 73 . Human breast cancer cells displaying silenced expression of miR-126 were shown to upregulate a set of miR-126 target genes -IGFBP2, MERTK and PITPNC1 -molecules that individually and collectively correlate in expression with human metastatic progression 73 (Fig. 3b) . These previously uncharacterized angiogenesis genes were shown to modulate the cell-extrinsic recruitment of endothelial cells by forming two divergent signalling pathways that emanate from cancer cells and engage endothelial cells. Cancercell-secreted IGFBP2 was shown to promote endothelial cell migration by driving IGF1-dependent activation of the endothelial IGF1 receptor (IGF1-R). PITPNC1, a phospho-inositide binding protein 106 , was found to promote endothelial cell migration by enhancing extracellular IGFBP2 levels. Finally, the receptor tyrosine kinase MERTK was shown to be proteolytically cleaved from the surface of cancer cells and released into the extracellular space. This MERTK ectodomain promoted endothelial cell migration by acting as a decoy receptor and sequestering circulating GAS6 -a molecule shown to inhibit endothelial cell migration through its action on endothelial MERTK receptors 73 ( Fig. 3b) . The metastasis-suppressive role of miR-126 and its clinical association with human metastatic relapse were recently validated in a mouse xenograft model of breast cancer metastasis as well 107 . This report found that, in addition to its ability to suppress angiogenesis -which was previously demonstrated for human breast cancer lines of triple-negative 73 , luminal 73, 108 and HER-2-positive 73 backgrounds, as well as for a variety of other cancer types such as lung 72 and oral 109 carcinomas -miR-126 overexpression can reduce mesenchymal stem cell (MSC) and monocyte content in primary xenograft tumours established by mouse 4T1 cells 107 . Interestingly, miR-126 silencing did not enhance monocyte or leukocyte recruitment by human breast cancer cells in vivo 73 , suggesting that the inflammatory cell recruitment observed by these investigators may be limited to the 4T1 mouse system or be the consequence of overexpression effects.
recruitment (MER), the ability of cancer cells to recruit endothelial cells to incipient metastases in vivo
Other metastasis-regulatory miRNAs probably govern additional noncell-autonomous phenotypes by altering the tumour microenvironment. For instance, a recent report suggested a cell-extrinsic role for miR-29b, an miRNA transcriptionally driven by GATA3 whose expression is reduced in breast cancer 110 . This miRNA, which was also shown to inhibit prostate 111 and liver cancer metastasis 112 as well as breast cancer metastasis 110 , was found to target a set of genes that had been previously implicated in cell-extrinsic processes such as angiogenesis and collagen remodelling 110 ( Table 1) . Some miRNAs may even directly impact neighbouring cell types, as is the case for miR-9, which was shown to regulate endothelial cell migration through its secretion from cancer cells inside microvesicles 113 . Such microvesicles or exosomes have also been found to contain multiple proteins that could modulate the tumour microenvironment [114] [115] .
Convergent control of metastatic progression by multiple miRNAs Nearly all previously described metastasis-regulatory miRNAs act through divergent targeting of multiple genes. However, recent work has delineated a network of miRNAs that drive metastasis through convergent targeting of functionally coupled genes 102 (Fig. 3c) . Gain-and loss-offunction approaches demonstrated that miR-199a-3p, miR-199a-5p and miR-1908 promote metastasis of multiple human melanoma lines of diverse mutational backgrounds. The combined expression of the three miRNAs exhibited stronger prognostic capacity in predicting metastatic outcomes than each individual miRNA. These findings, which are suggestive of miRNA cooperativity in human metastatic progression, were corroborated by in vivo loss-of-function studies. Inhibition of each miRNA suppressed metastasis by roughly 4-fold, and concurrent silencing of the three miRNAs decreased metastatic colonization by more than 70-fold, attesting to their remarkable functional cooperativity 102 . miR-199a-3p, miR-199a-5p and miR-1908 were shown to convergently target two phenotypically related genes, the heat shock factor DNAJA4 and the metabolic protein apolipoprotein-E (ApoE). Consistent with these two genes acting as the key downstream effectors of the miRNAs, the metastasis-suppressive effects observed following miRNA inhibition were rescued by depletion of either DNAJA4 or ApoE. Interestingly, DNAJA4 was shown to suppress metastasis through positive regulation of ApoE expression, establishing ApoE as the central node in this convergent miRNA regulatory network. The metastasis-suppressive role of ApoE was corroborated by the correlation observed between ApoE expression levels and human melanoma progression outcomes, by the ability of ApoE to abrogate metastasis of multiple human melanoma lines, and by the robust enhancement of metastasis following genetic deletion of ApoE in immunocompetent mice. ApoE, which is secreted by melanoma cells, was shown to suppress both melanoma cell-intrinsic and cell-extrinsic metastatic phenotypes. The cell-autonomous targeting of melanoma LRP1 receptors by ApoE decreased melanoma cell invasion, whereas its non-cell-autonomous engagement of endothelial LRP8 receptors inhibited MER (ref. 102) (Fig. 3c) . These findings provide an example of a convergent miRNA regulatory network, with miRNAs playing dual cell-intrinsic and cell-extrinsic roles in metastatic progression. Interestingly, MER has emerged as a common feature driving both breast cancer and melanoma metastasis 73, 102 .
Divergent versus convergent metastasis regulation by miRNAs
Initial findings on the connectivity of miRNA regulatory networks suggested that they control metastasis through their ability to coordinately target multiple genes. Divergent metastasis control was demonstrated for miR-335 (ref. 6 ) and subsequently shown to be the pervasive mode of regulation for many other miRNAs, including miR-31 (ref. 77) , the miR-200 family [88] [89] [90] [91] [92] [93] , miR-9 (refs 94-95), miR-21 (refs 96-98) , let-7 (refs 104-105) and miR-126 (ref. 73) . The advantage that such divergent gene targeting confers to metastasis is conceptually intuitive: a single miRNA could coordinately regulate the expression of multiple genes, all of which participate in a common metastatic phenotype. The concurrent silencing of a set of genes by a given miRNA leads to more profound modulation of the phenotype than independent silencing of individual genes.
In contrast, the pervasiveness of convergent target regulation by multiple unique miRNAs in other metastasis models remains to be explored. The advantage of convergent miRNA regulation stems from the maximum silencing of a single gene, such as ApoE, that is the central determinant of the metastatic phenotype 102 . Cooperative targeting by multiple miRNAs ensures more robust gene expression control than that afforded by a single miRNA, and may have an added advantage in cases where genetic inactivation of a key metastasis-suppressive factor may not be tolerated by cells. The divergent and convergent models of connectivity that characterize miRNA regulatory networks in metastasis are unlikely to be coincidental. Instead, they could have arisen from evolutionarily conserved connectivity that is likely to serve important roles during development and physiology, making them vulnerable to co-option during pathogenesis.
Mechanisms underlying aberrant miRNA expression in metastasis Altered miRNA expression results from diverse mechanisms operating during metastatic progression. For instance, the metastasis suppressor miR-335 (Fig. 1a) was found to be inactivated in human breast cancer through genetic deletion of the miR-335 locus as well as epigenetically driven transcriptional silencing of the locus by promoter hypermethylation 59 . Moreover, several metastasis-promoting miRNAs have been shown to be direct targets of well-known oncogenic transcription factors. miR-10b (Fig. 2a) and miR-9 (Fig. 2d) 91, 116 (Fig. 2c) . The metastasis suppressor miR-34 was also shown to form a double-negative feedback loop with one of its targets, the oncogenic transcription factor SNAIL (ref. 117) .
The components of the miRNA processing machinery have also been implicated in cancer progression. Consistent with expression analyses indicating downregulation of Dicer and Drosha in breast cancer progression 54, 118 , direct repression of Dicer by miR-103/107 enhanced breast cancer metastasis 119 , whereas transcriptional induction of Dicer by Tap63 suppressed metastasis 120 . Furthermore, inactivating mutations in Exportin-5 have been identified in a small subset of human colorectal tumors, leading to defective miRNA nuclear export 121 . Finally, small RNA-binding proteins that regulate the processing of specific miRNAs have also been implicated in metastasis. For instance, LIN-28, which binds and destabilizes the let-7 pre-miRNA, was shown to promote breast cancer metastasis 104 . These findings reveal a diversity of inactivating and activating molecular mechanisms governing the expression of metastasis-regulatory miRNAs, which underscores their importance among the regulatory molecules expressed by cancer cells.
Translational potential for basic discoveries
The ability of small RNAs to regulate gene expression has generated much hope for exploiting them as potential therapeutic target molecules in human diseases. The two main problems that have hindered the clinical translation of miRNAs are their limited half-lives in serum and their limited delivery into target tissues. Although there is no broadly accepted or applied methodological approach for systemic in vivo delivery of therapeutic miRNAs, two recent reports raise renewed hope by using an alternative approach to 'naked' nucleic acid delivery, which involves viral-based delivery methods 122, 123 . Adeno-associated viral delivery of miR-26a, for instance, was found to significantly suppress tumorigenesis in a murine model of hepatocellular carcinoma -a cancer known to display reduced miR-26a expression 122 .
In vivo inhibition of miRNAs through the systemic administration of locked nucleic acids (LNAs) has progressed to a much greater degree in the pre-clinical and clinical arenas than miRNA delivery 124 . For instance, systemic delivery of an LNA targeting miR-122 -a hepatic miRNA that regulates cholesterol -led to significant decreases in plasma cholesterol in non-human primates 125 . Therapeutic targeting of this miRNA, which is also required for hepatitis C virus (HCV) replication, was also shown to successfully suppress HCV viremia 126 . These successes have motivated studies involving therapeutic LNA delivery in pre-clinical cancer models. To this end, systemic delivery of an LNA targeting the breast cancer metastasis promoter miR-10b was shown to suppress metastasis 86 .
Recently, silencing of miR-199a-3p, miR-199a-5p and miR-1908 using a cocktail of LNAs was found to dramatically suppress melanoma metastasis 102 , a condition that currently lacks effective therapeutic options.
Summary and future directions miRNAs have been established as key metastasis regulators by numerous investigators working on diverse cancer types, with concepts such as divergent and convergent control by miRNA regulatory networks emerging more recently. Metastasis-regulatory miRNAs have been found to govern both cell-intrinsic processes and cell-extrinsic features of the tumour microenvironment. The prognostic capacity of these non-coding RNAs in predicting human metastatic outcomes suggests an active role for them in human cancer progression. Most importantly, miRNAs have accelerated the discovery of genes and signalling pathways mediating metastasis. These basic explorations will expedite translational efforts aimed at reducing cancer mortality.
